SAN FRANCISCO (AFX) -- Bristol-Myers Squibb Co. after Wednesday's closing bell said Baraclude demonstrated greater benefit in treating nucleoside-naive chronic hepatitis B patients compared to lamivudine, according to two studies published in the New England Journal of Medicine. Trials found that Baraclude treatment resulted in significantly greater improvements in liver histology and reductions of HBV DNA to undetectable levels compared to treatment with lamivudine, the most commonly used antiviral therapy for treatment of chronic hepatitis B worldwide, Bristol-Myers added. This story was supplied by MarketWatch. For further information see www.marketwatch.com.